Suppr超能文献

伴有顽固性视网膜内囊肿的厚脉络膜新生血管病变的治疗与特征

Treatment and Characteristics of Pachychoroid Neovasculopathy Accompanying Recalcitrant Intraretinal Cysts.

作者信息

Choi Moon Young, Lee Won Ki

机构信息

Retina Center, Nune Eye Hospital, Seoul, KOR.

出版信息

Cureus. 2024 Aug 30;16(8):e68174. doi: 10.7759/cureus.68174. eCollection 2024 Aug.

Abstract

PURPOSE

To evaluate the clinical characteristics associated with chronic pachychoroid neovasculopathy (PNV) accompanying recalcitrant intraretinal cysts.

METHODS

This is a retrospective, single-center, case-series study involving 20 eyes of 18 patients with PNV who did not respond to bevacizumab or ranibizumab and had to switch to aflibercept. Optical coherence tomography images were assessed before and after switching of intravitreal injection drug.

RESULTS

The intraretinal cysts involved the outer nuclear layer and inner nuclear layer in 15 patients (75.0%), and involved only the inner nuclear layer in five patients (25.0%). All participants showed retinal pigment epithelium atrophy and outer retinal layer defect including external limiting membrane defect co-localized to the intraretinal cystic lesion. With the initial injection, bevacizumab and ranibizumab injections did not show a significant decrease in choroidal thickness (CT). Twenty (100.0%) patients showed poor response of intraretinal cyst response (IRCR). After a switch to aflibercept, IRCR was good in 17 (85.0%) patients and poor in three (15.0%) patients. Reduction of CT was great in aflibercept injections (from 229.0 μm to 204.0 μm, median, p < 0.001). Best-corrected visual acuity did not show significant improvement before or after switching drugs.

CONCLUSION

Intravitreal aflibercept injections were more effective in the reduction of CT and IRCR than bevacizumab and ranibizumab injections. The primary source of the intraretinal cyst fluid could be from the choroid.

摘要

目的

评估与伴有顽固性视网膜内囊肿的慢性脉络膜新生血管病变(PNV)相关的临床特征。

方法

这是一项回顾性、单中心、病例系列研究,纳入了18例PNV患者的20只眼,这些患者对贝伐单抗或雷珠单抗无反应,不得不改用阿柏西普。在玻璃体腔内注射药物更换前后评估光学相干断层扫描图像。

结果

15例患者(75.0%)的视网膜内囊肿累及外核层和内核层,5例患者(25.0%)仅累及内核层。所有参与者均表现出视网膜色素上皮萎缩和外层视网膜缺损,包括与视网膜内囊性病变共定位的外界膜缺损。初次注射时,贝伐单抗和雷珠单抗注射后脉络膜厚度(CT)无显著降低。20例患者(100.0%)的视网膜内囊肿反应(IRCR)较差。改用阿柏西普后,17例患者(85.0%)的IRCR良好,3例患者(15.0%)较差。阿柏西普注射后CT降低明显(从中位数229.0μm降至204.0μm,p<0.001)。换药前后最佳矫正视力均无显著改善。

结论

玻璃体腔内注射阿柏西普在降低CT和改善IRCR方面比注射贝伐单抗和雷珠单抗更有效。视网膜内囊液的主要来源可能是脉络膜。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5b2/11439126/10a3ae3da2dd/cureus-0016-00000068174-i01.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验